The causal association between seven drugs and erectile dysfunction: a Mendelian randomization study

Area of Science:

• Pharmacogenomics
• Epidemiology
• Genetic Epidemiology

Background:

• Conflicting evidence exists regarding drug-induced erectile dysfunction (ED).
• Previous studies have debated the accuracy of conclusions linking certain medications to ED.
• Understanding genetically predicted associations is crucial for accurate risk assessment.

Purpose of the Study:

• To explore genetically predicted associations between drug treatments and ED.
• To evaluate the causal relationship between specific drug regimens and ED risk.
• To utilize genome-wide association study (GWAS) data for robust analysis.

Main Methods:

• Employed a two-sample Mendelian randomization (MR) design.
• Analyzed pooled GWAS data for 40 drugs and ED risk.
• Utilized MR-Egger, weighted median, and inverse variance weighted (IVW) methods, alongside pleiotropy and heterogeneity tests.

Main Results:

• Identified potential causal relationships between ED and simvastatin, ramipril, metformin, gliclazide, atorvastatin, and atenolol.
• Aspirin showed a borderline association (p > 0.05) after SNP exclusion, requiring further investigation.
• No significant causal relationships were found for the remaining 33 drugs analyzed.

Conclusions:

• Genetically predicted associations suggest potential causal links between specific drugs (simvastatin, ramipril, metformin, gliclazide, atorvastatin, atenolol) and ED.
• These findings highlight the need for further research to confirm the identified drug-ED relationships.
• The study provides valuable insights into the genetic underpinnings of drug-induced ED.